Pemetrexed approved for use in first-line treatment of most common lung cancer
Johannesburg, 7 October 2009:
Lilly today announced that their pemetrexed for injection has been approved for a histologically- based use in the first-line treatment of advanced non-small-cell lung cancer (NSCLC)1, the most common form of lung cancer2.
By submitting manuscripts to SAJGO, authors of original articles are assigning copyright to the South African Society of Gynaecologic Oncology (SASGO). Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJGO for educational and research purposes without obtaining permission.